Tiziana life sciences to participate in a fireside chat at the b. riley securities 2022 virtual neuro & ophthalmology conference

New york, april 26, 2022 (globe newswire) -- tiziana life sciences ltd (nasdaq: tlsa) ("tiziana" or the "company"), a clinical-stage biopharmaceutical company developing alternative routes of immunotherapy with a focus on innovative drugs for neurodegenerative diseases, including treatment with intranasal foralumab for secondary progressive multiple sclerosis, today announced its chief executive officer and chief scientific officer, kunwar shailubhai, ph.d., will participate in a fireside chat at the b. riley securities 2022 virtual neuro & ophthalmology conference on wednesday, april 27, 2022 at 2:30 p.m. et (u.s. and canada) to provide company updates.
TLSA Ratings Summary
TLSA Quant Ranking